The Disease Severity Index from HepQuant DuO and Likelihood for Large Esophageal Varices in the **SHUNT-V Study**

M.P. McRae¹, S.M. Helmke², and G.T. Everson² for the SHUNT-V Investigators

¹Custom Diagnostic Solutions LLC, Houston, TX, USA; ²HepQuant LLC, Denver, CO, USA

Background

- Endoscopy (EGD) is indicated in patients with cirrhosis to check for large esophageal varices (LEVs) that need treatment.
- Prevalence of LEVs at EGD in Child-Pugh (CP) A cirrhosis is ~10%.
- The HepQuant SHUNT test quantifies liver function and portal-systemic shunting.
- An oral-only version (HepQuant DuO) was developed to simplify test administration and reduce variability.

HepQuant DuO parameters were sensitive in detecting presence and size of varices.						
	All Subjects (N=238)	No Varices (N=135)	Small Varices (N=76)	Large Varices (N=27)	p-value	
Laboratory Values						
Albumin, g dL ⁻¹	4.23 ± 0.43	4.31 ± 0.41	4.18 ± 0.45	4.00 ± 0.42	0.0014	
Alk. Phos., U L ⁻¹	100.53 ± 51.86	94.61 ± 37.64	102.87 ± 69.34	123.11 ± 50.22	0.0294	
ALT, U L ^{−1}	38.42 ± 34.24	39.90 ± 41.00	37.32 ± 24.28	34.22 ± 18.15	0.6945	
AST, U L ^{−1}	42.11 ± 24.98	41.03 ± 25.69	42.47 ± 25.28	46.44 ± 20.56	0.5855	
Bilirubin, mg dL ⁻¹	0.75 ± 0.44	0.70 ± 0.41	0.74 ± 0.43	1.00 ± 0.52	0.0042	
Creatinine, mg dL ⁻¹	0.90 ± 0.29	0.89 ± 0.25	0.93 ± 0.38	0.89 ± 0.19	0.6377	
Platelets, ×10 ³ µL ⁻¹	152 ± 68	169 ± 68	142 ± 61	97 ± 53	<0.0001	
Prothrombin time, INR	1.09 ± 0.15	1.08 ± 0.13	1.11 ± 0.18	1.13 ± 0.10	0.1076	
APRI	0.87 ± 0.66	0.72 ± 0.53	0.87 ± 0.62	1.56 ± 0.92	<0.0001	
FIB-4	3.63 ± 2.67	2.98 ± 2.06	3.70 ± 2.23	6.61 ± 4.10	<0.0001	
Clinical Scores						
Child-Pugh score	5.14 ± 0.35	5.11 ± 0.32	5.12 ± 0.33	5.33 ± 0.48	0.0076	
MELD score	7.84 ± 2.22	7.58 ± 1.93	8.15 ± 2.69	8.27 ± 1.93	0.1198	
HepQuant DuO						
DSI	22.56 ± 7.53	20.49 ± 6.64	23.64 ± 7.71	29.88 ± 6.07	<0.0001	
SHUNT% (%)	38.57 ± 15.61	34.23 ± 13.29	40.97 ± 16.30	53.52 ± 14.02	<0.0001	
Hepatic Reserve (%)	71.33 ± 19.23	76.84 ± 17.05	68.27 ± 19.18	52.40 ± 15.94	<0.0001	
HFR _P (mL/min/kg)	11.02 ± 6.86	12.54 ± 6.29	10.29 ± 7.70	5.52 ± 2.94	<0.0001	

Results

Aims

- To evaluate the diagnostic performance of HepQuant DuO Test in ruling out LEVs in CP A cirrhosis
- To compare performance of HepQuant DuO and HepQuant SHUNT tests

Methods

Subjects

- 238 patients with CP A cirrhosis in the SHUNT-V Study
- 50% MASLD/MASH, 24% HCV, 18% alcoholic liver disease
- 64% obese, 85% overweight, 54% diabetes


SHUNT Test Administration

- 13C-cholate injected by IV and d4-cholate administered orally
- Blood sampled at 0, 5, 20, 45, 60, 90 min. for serum cholate

Applying the DSI ≤18.3 cutoff to SHUNT-V subjects would have missed 1 case and prevented 84 EGDs.

Diagnostic Performance (95% CI) of DuO (DSI ≤18.3) in SHUNT-V CP A Subjects (N=238) 0.96 (0.81-1.00) Sensitivity 0.39 (0.33-0.46) Specificity Positive Predictive Value 0.17 (0.15-0.19) Negative Predictive Value 0.99 (0.92-1.00) Positiva Likelihood Ratio 150(130-181)

Monotonic, stepwise increase in DSI with increasing risk for LEVs



HepQuant Test Versions

- SHUNT V1.1: 13C- and d4-CA concentrations at 20, 45, 60, and 90 min. were calculated based on cubic spline and exponential fits [1]
- <u>DuO</u>: only d4-CA concentrations at 20 and 60 min., calculated based on compartmental model [2]

Test Parameters

- Disease severity index (DSI), portal-systemic shunt (SHUNT%), Hepatic Reserve, and Portal Hepatic Filtration Rate (HFR_P)
- DSI cutoff of ≤18.3 was prespecified based on >95% sensitivity for LEVs in the HALT-C Trial QLFT ancillary study

Statistical Analysis

Differences between subgroups analyzed by ANOVA (continuous data) and Chi-square (categorical data)

Positive Likelinood Ratio	1.59 (1.39-1.81)
Negative Likelihood Ratio	0.09 (0.01-0.65)
Missed LEVs, n (%)*	1 (3.7%)
EGDs Prevented, n (%)	84 (35.3%)




Pairwise comparison of AUROC for DSI in detecting LEVs in SHUNT-V CP A (N=238)

	AUROC (95% CI)	p value
DuO	0.809 (0.737-0.882)	0.3169
SHUNT V1.1	0.817 (0.749-0.885)	-

DSI from DuO demonstrated significant association with finding LEVs at endoscopy (p<0.001).

Probability of LEVs, Based on DSI



- DSI from lean and overweight controls plotted alongside subjects with no, small, or large esophageal varices
- Diagnostic performance for ruling out LEVs (AUROC, sensitivity, specificity, PPV, NPV)
- AUROCs for DuO and SHUNT V1.1 for ruling out LEVs compared by DeLong method
- Univariate logistic regression of DSI for presence of LEVs

Juant

Transforming Liver Health

Conclusions

- HepQuant DuO test parameters of liver function and physiology correlate with presence and size of esophageal varices.
- Knowing the likelihood that a given DSI is associated with a particular risk of LEVs is highly relevant to clinical decision making.
- **DuO and SHUNT V1.1 were statistically equivalent in the detection of LEVs.**
 - **DuO missed one LEV case that was detected by SHUNT V1.1.**
 - Application of DSI ≤18.3 would have avoided EGDs in 35% for DuO versus 31% for SHUNT V1.1.
- DuO is easier to administer and less invasive, thus, having the potential to be more widely accepted by care providers administering the test and by patients receiving the test.

References

[1] Everson GT et al. Aliment. Pharmacol. Ther. 2007; 26:401-410. [2] McRae MP et al. Transl. Res. 2023; 252:53-63.

Contact Information

Shailesh Chavan (CMO): shailesh.chavan@hepquant.com Steve M. Helmke (CSO): steve.helmke@hepquant.com Michael P. McRae: michael.mcrae@hepquant.com

Disclosures

MPM is a paid consultant for HepQuant LLC. SMH and GTE are employees and equity members of HepQuant LLC. All authors have provisional patents pending. HepQuant tests are not FDA approved and are for investigational use only under FDA guidelines for investigational device exemption (IDE).